SGLT2 Inhibitors Market Size, Share & Trends Analysis Report By Drug (Jardiance, Farxiga, Inpefa, Invokana), By Indication (Type 2 Diabetes, Cardiovascular), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug
  • 1.2.2. Indication
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug and Indication outlook
  • 2.2.2. Distribution Channel outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. SGLT2 Inhibitors Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of target disease
    • 3.2.1.2. Technological advancements in drug development
    • 3.2.1.3. Growing awareness and diagnosis
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of drug development
    • 3.2.2.2. Stringent regulatory policies for drug approval
• 3.3. SGLT2 Inhibitors Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Target population analysis

Chapter 4. SGLT2 Inhibitors Market: Drug Estimates & Trend Analysis

• 4.1. Global SGLT2 Inhibitors Market: Drug Dashboard
• 4.2. Global SGLT2 Inhibitors Market: Drug Movement Analysis
• 4.3. Global SGLT2 Inhibitors Market By Drug, Revenue
• 4.4. Jardiance (empagliflozin)
  • 4.4.1. Jardiance (empagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Farxiga (dapagliflozin)
  • 4.5.1. Farxiga (dapagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Invokana (canagliflozin)
  • 4.6.1. Invokana (canagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Inpefa (sotagliflozin)
  • 4.7.1. Inpefa (sotagliflozin) market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Qtern (dapagliflozin/saxagliptin)
  • 4.8.1. Qtern (dapagliflozin/saxagliptin) market estimates and forecasts, 2021 - 2033 (USD Million)
• 4.9. Other SGLT2 Inhibitors
  • 4.9.1. Other SGLT2 inhibitors market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. SGLT2 Inhibitors Market: Indication Estimates & Trend Analysis

• 5.1. Global SGLT2 Inhibitors Market: Indication Dashboard
• 5.2. Global SGLT2 Inhibitors Market: Indication Movement Analysis
• 5.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, By Indication, Revenue (USD Million)
• 5.4. Type 2 Diabetes
  • 5.4.1. Type 2 diabetes market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Cardiovascular
  • 5.5.1. Cardiovascular market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Chronic Kidney Disease (CKD)
  • 5.6.1. Chronic kidney disease (CKD) market estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. SGLT2 Inhibitors Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global SGLT2 Inhibitors Market: Distribution Channel Dashboard
• 6.2. Global SGLT2 Inhibitors Market: Distribution Channel Movement Analysis
• 6.3. Global SGLT2 Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online pharmacies market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. SGLT2 Inhibitors Market: Regional Estimates & Trend Analysis By Drug, Indication, and Distribution Channel

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Boehringer Ingelheim International GmbH.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. AstraZeneca
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Merck & Co., Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. TheracosBio, LLC
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Lexicon Pharmaceuticals, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Eli Lilly and Company
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Bristol-Myers Squibb Company
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Glenmark Pharmaceuticals Ltd
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviation
• Table 2 North America SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
• Table 3 North America SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 4 North America SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 5 North America SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 6 U.S. SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 7 U.S. SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 8 U.S. SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 9 Canada SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 10 Canada SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 11 Canada SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 12 Mexico SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 13 Mexico SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 14 Mexico SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 15 Europe SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
• Table 16 Europe SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 17 Europe SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 18 Europe SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 19 Germany SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 20 Germany SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 21 Germany SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 22 UK SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 23 UK SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 24 UK SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 25 France SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 26 France SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 27 France SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 28 Italy SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 29 Italy SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 30 Italy SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 31 Spain SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 32 Spain SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 33 Spain SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 34 Denmark SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 35 Denmark SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 36 Denmark SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 37 Sweden SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 38 Sweden SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 39 Sweden SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 40 Norway SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 41 Norway SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 42 Norway SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 43 Asia Pacific SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
• Table 44 Asia Pacific SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 45 Asia Pacific SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 46 Aisa Pacific SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 47 China SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 48 China SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 49 China SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 50 Japan SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 51 Japan SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 52 Japan SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 53 India SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 54 India SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 55 India SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 56 South Korea SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 57 South Korea SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 58 South Korea SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 59 Australia SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 60 Australia SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 61 Australia SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 62 Thailand SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 63 Thailand SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 64 Thailand SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 65 Latin America SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
• Table 66 Latin America SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 67 Latin America SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 68 Latin America SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 69 Brazil SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 70 Brazil SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 71 Brazil SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 72 Argentina SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 73 Argentina SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 74 Argentina SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 75 MEA SGLT2 Inhibitors market, by region, 2021 - 2033 (USD Million)
• Table 76 MEA SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 77 MEA SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 78 MEA SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 79 South Africa SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 80 South Africa SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 81 South Africa SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 82 Saudi Arabia SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 83 Saudi Arabia SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 84 Saudi Arabia SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 85 UAE SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 86 UAE SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 87 UAE SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)
• Table 88 Kuwait SGLT2 Inhibitors market, by drug, 2021 - 2033 (USD Million)
• Table 89 Kuwait SGLT2 Inhibitors market, by indication, 2021 - 2033 (USD Million)
• Table 90 Kuwait SGLT2 Inhibitors market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 SGLT2 Inhibitors market: market outlook
• Fig. 14 SGLT2 Inhibitors competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 SGLT2 Inhibitors market driver impact
• Fig. 18 SGLT2 Inhibitors market restraint impact
• Fig. 19 SGLT2 Inhibitors market: Drug movement analysis
• Fig. 20 SGLT2 Inhibitors market: Drug outlook and key takeaways
• Fig. 21 Jardiance (empagliflozin) market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 22 Farxiga (dapagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 23 Steglatro (ertugliflozin) market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 24 Invokana (canagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 25 Brenzavvy (bexagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 26 Inpefa (sotagliflozin) estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 27 Other SGLT2 inhibitors estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 28 SGLT2 Inhibitors market: Indication movement analysis
• Fig. 29 SGLT2 Inhibitors market: Indication outlook and key takeaways
• Fig. 30 Type 2 diabetes market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 31 Cardiovascular market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 32 Chronic kidney disease (CKD) market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 33 Others market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 34 SGLT2 Inhibitors market: Distribution channel movement analysis
• Fig. 35 SGLT2 Inhibitors market: Distribution channel outlook and key takeaways
• Fig. 36 Hospital pharmacies market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 37 Retail pharmacies market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 38 Online pharmacies market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 39 Global SGLT2 Inhibitors market: Regional movement analysis
• Fig. 40 Global SGLT2 Inhibitors market: Regional outlook and key takeaways
• Fig. 41 Global SGLT2 Inhibitors market share and leading players
• Fig. 42 North America, by country
• Fig. 43 North America market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 44 U.S. key country dynamics
• Fig. 45 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 46 Canada key country dynamics
• Fig. 47 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 48 Mexico key country dynamics
• Fig. 49 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 50 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 51 UK key country dynamics
• Fig. 52 UK market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 53 Germany key country dynamics
• Fig. 54 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 55 France key country dynamics
• Fig. 56 France market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 57 Italy key country dynamics
• Fig. 58 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 59 Spain key country dynamics
• Fig. 60 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 61 Denmark key country dynamics
• Fig. 62 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 63 Sweden key country dynamics
• Fig. 64 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 65 Norway key country dynamics
• Fig. 66 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 67 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 68 China key country dynamics
• Fig. 69 China market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 70 Japan key country dynamics
• Fig. 71 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 72 India key country dynamics
• Fig. 73 India market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 74 Thailand key country dynamics
• Fig. 75 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 76 South Korea key country dynamics
• Fig. 77 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 78 Australia key country dynamics
• Fig. 79 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 80 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 81 Brazil key country dynamics
• Fig. 82 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 83 Argentina key country dynamics
• Fig. 84 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 85 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 86 South Africa key country dynamics
• Fig. 87 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 88 Saudi Arabia key country dynamics
• Fig. 89 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 90 UAE key country dynamics
• Fig. 91 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 92 Kuwait key country dynamics
• Fig. 93 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
• Fig. 94 Market share of key market players - SGLT2 Inhibitors market